Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke
Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke: a Randomized Controlled Pilot Trial
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Daniel KY Zheng, PhD
- Número de teléfono: +852 53205956
- Correo electrónico: daniel.zheng@polyu.edu.hk
Copia de seguridad de contactos de estudio
- Nombre: Daniel KY Zheng, PhD
- Número de teléfono: +852 53205956
- Correo electrónico: kangyong.zheng@connect.polyu.hk
Ubicaciones de estudio
-
-
Hong Kong
-
Hong Kong, Hong Kong, Porcelana, 999077
- The Hong Kong Polytechnic University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Aged between 18-80 years with onset of stroke within one and twelve months of enrollment and having overactive bladder (OAB) symptoms;
- Experiencing moderate (scoring 6-11 points on the Overactive Bladder Symptom Score [OABSS]) to severe OAB (scoring ≥ 12 points on OABSS);
- Obtaining a Mini-Mental State Examination (MMSE) score of ≥ 24.
Exclusion Criteria:
- Presence of metallic implants in the cranium, intracardiac lines, increased intracranial pressure, cardiac pacemaker, cochlear implants, tumour, and skull abnormalities;
- Family history of epilepsy/seizures;
- Contraindications to transcranial magnetic stimulation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Active transcranial direct current stimulation (tDCS) + pelvic floor muscle training (PFMT)
|
Participants will receive active tDCS (1.5 mA for 20 minutes; current density 0.06 mA/cm²) 3 times per week for 8 weeks.
tDCS will be conducted using two 5 x 7 cm² surface electrodes connected to a battery-powered stimulator (Neuroelectrics Instrument Controller, v 2.0).
The anodal electrode will be placed over the supplementary motor area, and the cathodal electrode over the contralateral supraorbital region.
Immediately following tDCS, participants will receive supervised, individual (1:1) PFMT for 30 minutes per session, consisting of pelvic floor contraction exercises (contracting the urethra/shortening the penis and controlling passage of gas), each held for 10 seconds and followed by 10 seconds of relaxation.
PFMT will be performed 3 times per week for 8 weeks.
|
|
Comparador falso: Sham transcranial direct current stimulation (tDCS) + pelvic floor muscle training (PFMT)
|
Immediately following tDCS, participants will receive supervised, individual (1:1) PFMT for 30 minutes per session, consisting of pelvic floor contraction exercises (contracting the urethra/shortening the penis and controlling passage of gas), each held for 10 seconds and followed by 10 seconds of relaxation.
PFMT will be performed 3 times per week for 8 weeks.
Participants will receive sham tDCS (active current for 30 seconds, then turned off) 3 times per week for 8 weeks.
tDCS will be conducted using two 5 x 7 cm² surface electrodes connected to a battery-powered stimulator (Neuroelectrics Instrument Controller, v 2.0).
The anodal electrode will be placed over the supplementary motor area, and the cathodal electrode over the contralateral supraorbital region.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overactive bladder symptoms severity
Periodo de tiempo: Baseline and post-intervention at 8 weeks
|
Overactive bladder symptoms severity will be assessed using Overactive Bladder Symptom Score (OABSS).
The total score of OABSS ranges from 0 to 15, with a higher score indicating higher symptom severity.
|
Baseline and post-intervention at 8 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recruitment Rate
Periodo de tiempo: Through study completion, an average of 1 year.
|
Number of participants recruited and screened per week during the recruitment period.
The unit of measure is participants/week.
|
Through study completion, an average of 1 year.
|
|
Time to Complete Recruitment
Periodo de tiempo: Through study completion, an average of 1 year.
|
Total time required to recruit the full study sample.
The unit of measure is weeks.
|
Through study completion, an average of 1 year.
|
|
Retention Rate
Periodo de tiempo: Baseline to 8 weeks
|
Percentage of enrolled participants who complete assessments at 8 weeks post-intervention, calculated as (number completing 8-week assessment / number enrolled) × 100.
The unit of measure is %.
|
Baseline to 8 weeks
|
|
Adherence to Intervention
Periodo de tiempo: Baseline to 8 weeks
|
Percentage of total prescribed intervention sessions attended, calculated as (number of sessions attended / number of sessions prescribed) × 100.
The unit of measure is %.
|
Baseline to 8 weeks
|
|
Adverse Events
Periodo de tiempo: Baseline to 8 weeks
|
Number of participants in each group who experience adverse events, monitored throughout the intervention.
|
Baseline to 8 weeks
|
|
Detrusor Wall Thickness
Periodo de tiempo: Baseline and post-intervention at 8 weeks
|
Detrusor wall thickness measured using the Mindray Consona N9 ultrasound system (Sonos Medical Limited) with a convex transducer of 3-6 MHz.
An increase in detrusor wall thickness indicates detrusor overactivity.
The unit of measure is millimeter (mm).
|
Baseline and post-intervention at 8 weeks
|
|
Bladder Neck Elevation
Periodo de tiempo: Baseline and post-intervention at 8 weeks
|
Bladder neck elevation, a surrogate measure of pelvic floor muscle strength, will be measured using the Mindray Consona N9 ultrasound system (Sonos Medical Limited).
Greater bladder neck elevation indicates stronger pelvic floor muscle strength.
The unit of measure is millimeter (mm).
|
Baseline and post-intervention at 8 weeks
|
|
Health-Related Quality of Life
Periodo de tiempo: Baseline and post-intervention at 8 weeks
|
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire.
The score ranges from -0.864 to 1.0, where 1.0 indicates full health and higher scores indicate better health-related quality of life.
|
Baseline and post-intervention at 8 weeks
|
|
Healthcare Costs
Periodo de tiempo: Baseline and post-intervention at 8 weeks.
|
Healthcare Costs will be collected using the Client Service Receipt Inventory (CSRI) to calculate total healthcare-related costs per participant from both healthcare provider and societal perspectives.
The unit of measure is Hong Kong Dollars (HKD).
|
Baseline and post-intervention at 8 weeks.
|
|
Incontinence-related quality of life
Periodo de tiempo: Baseline and post-intervention at 8 weeks
|
Incontinence-related quality of life will be assessed using the Incontinence Quality of Life Questionnaire (I-QoL).
The I-QoL score ranges from 0-100, with higher scores indicating higher quality of life.
|
Baseline and post-intervention at 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Priya Kannan, PhD, The Hong Kong Polytechnic University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Síntomas del tracto urinario inferior
- Manifestaciones Urológicas
- Enfermedades de la vejiga urinaria
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Carrera
- Vejiga Urinaria Hiperactiva
Otros números de identificación del estudio
Otros números de identificación del estudio
- HSEARS20260727002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .